How to Help Your Patients Find Tetrabenazine in Stock: A Provider's Guide

For clinicians managing Huntington's disease patients on Tetrabenazine, one of the most common practical frustrations isn't the clinical management itself — it's the pharmacy access problem. Patients call your office because they can't fill their prescription. Your staff spends time troubleshooting insurance issues and hunting for specialty pharmacies. This guide gives you a practical, actionable framework for helping your patients get their Tetrabenazine reliably in 2026.

Step 1: Route Prescriptions to the Right Pharmacy From the Start

The single most impactful thing you can do to prevent access problems for Tetrabenazine patients is to route the prescription directly to an appropriate specialty pharmacy at the time of prescribing — not to a standard retail pharmacy.

Recommended specialty pharmacies for Tetrabenazine:

CVS Specialty — widely accepted by commercial insurance, handles PA coordination

Accredo (Express Scripts) — required specialty pharmacy for Cigna and many Express Scripts-administered plans

Walgreens Specialty Pharmacy — serves multiple insurance networks, option for Aetna and BCBS patients

CuraScript — specialty network with experience in rare disease and movement disorder medications

Check the patient's insurance formulary before routing. Each insurer mandates a specific specialty pharmacy for Tetrabenazine. Sending to the wrong one can delay the fill by days.

Step 2: Get Prior Authorization Right the First Time

Prior authorization (PA) for Tetrabenazine is required by virtually all commercial insurance plans. A PA application that is incomplete or lacks the right clinical documentation is a leading cause of fill delays. Prepare your PA submission to include:

Confirmed Huntington's disease diagnosis with ICD-10 code G10 (Huntington's disease)

Documentation of chorea severity and functional impact (UHDRS scores are helpful)

Prescriber specialty (neurologist or movement disorder specialist strengthens the application)

Documentation that depression and suicidality have been screened and addressed (per the boxed warning requirements)

CYP2D6 genotype results if prescribing above 50 mg/day

Step 3: Counsel Patients to Refill 7–10 Days Early

One of the most preventable causes of Tetrabenazine access crises is patients waiting until their last day of supply to refill. Because this is a specialty drug with limited pharmacy distribution, allow 7–10 extra days of lead time when counseling patients on refills. Build this into your discharge and follow-up instructions.

Setting patients up for 90-day mail-order supply — once they are on a stable dose — significantly reduces the refill burden and virtually eliminates the "out of stock" problem at the pharmacy level.

Step 4: Remind Patients About Cost Assistance Options

Tetrabenazine's list price can reach $4,000–$4,400 per month. Even with insurance, copays for specialty drugs can be burdensome. Remind patients about:

Lundbeck patient assistance program — for brand Xenazine in eligible uninsured/underinsured patients

GoodRx and SingleCare coupons — can reduce generic Tetrabenazine cash price to as low as $60 per fill

HDSA (Huntington's Disease Society of America) — patient advocacy organization that can connect patients with financial assistance resources

Step 5: Refer Patients to medfinder for Pharmacy Search Assistance

When patients call your office because they can't find Tetrabenazine, referring them to medfinder saves your staff time and gets the patient a faster answer. medfinder calls pharmacies in the patient's area to identify which ones have the medication in stock, and texts results directly to the patient. Visit medfinder.com/providers to learn more about how medfinder works and how to incorporate it into your patient communication workflows.

When to Consider Switching to a Tetrabenazine Alternative

If access problems are persistent, or if side effects (particularly depression, sedation, or parkinsonism) are limiting treatment, consider transitioning to deutetrabenazine (Austedo) or valbenazine (Ingrezza). See our companion post Tetrabenazine Shortage: What Providers Need to Know in 2026 for clinical switching guidance.